Yahoo Search Busca da Web

Entrar

Resultado da Busca

  1. onkuretherapeutics.com › about › teamOnKure Therapeutics Leadership Team

    Rich Woessner is Senior Vice President of Pharmacology at Onkure Therapeutics, working with discovery and clinical development teams to guide and implement in vivo pharmacology strategies for evaluation of preclinical stage compounds, and provide translational pharmacology data to inform clinical development strategies.

    • 6707 Winchester Circle, Boulder, 80301, Colorado
    • (720) 307-2892
    • richard woessner1
    • richard woessner2
    • richard woessner3
    • richard woessner4

  2. onkuretherapeutics.com › team › richard-woessnerRichard Woessner, Ph.D. - OnKure, Inc.

    Rich Woessner is Senior Vice President of Pharmacology at Onkure Therapeutics, working with discovery and clinical development teams to guide and implement in vivo pharmacology strategies for evaluation of preclinical stage compounds, and provide translational pharmacology data to inform clinical development strategies.

    • 6707 Winchester Circle, Boulder, 80301, Colorado
    • (720) 307-2892

  3. Imagens

    • Richard Woessner, Ph.D. - OnKure, Inc.
    • Richard Woessner
    • USAMuscle | Richard Woessner
    • Richard Woessner - Business Banker - Citi | LinkedIn
    • Richard Woessner Development

    Ver tudo

  4. theorg.com › org-chart › richard-woessnerRichard Woessner - SVP, Pharmacology at OnKure ... - The Org

    Rich Woessner is Senior Vice President of Pharmacology at OnKure, Inc. working with the scientific team to develop and implement in vivo pharmacology strategies to discover compounds.

    • SVP, Pharmacology
    • Onkure Therapeutics, Onkure Therapeutics

  5. pubmed.ncbi.nlm.nih.gov › 20032381ARRY-520, a novel KSP inhibitor with potent activity in ...

    Abstract. Aim: Profiling the efficacy and pharmacodynamic activity of the kinesin spindle protein (KSP) inhibitor ARRY-520 will aid the identification of responsive tumor types and pharmacodynamic profiles that correlate with activity.

    • Richard Woessner, Brian Tunquist, Christine Lemieux, Elizabeth Chlipala, Steve Jackinsky, Walter Dew...
    • 2009

  6. mdanderson.elsevierpure.com › en › publicationsTargeting the insulin-like growth factor-1 receptor to ...

    Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma. Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones, Richard Woessner, Chad C. Bjorklund, Wencai Ma, R. Eric Davis, Pei Lin, Hua Wang, Timothy L. Madden, Caimiao Wei, Veerabhadran Baladandayuthapani, Michael Wang, Sheeba K.

    • Deborah J. Kuhn, Zuzana Berkova, Richard J. Jones, Richard Woessner, Chad C. Bjorklund, Wencai Ma, R...
    • Blood
    • 2012
    • 11

  7. pubmed.ncbi.nlm.nih.gov › 32409420Conversion of ATP to adenosine by CD39 and CD73 in ... - PubMed

    Transplantable 5T33MM myeloma cells were used to determine the effect of inhibiting CD39, CD73 and A2AR in mice in vivo. Results: Elevated level of adenosine was found in BM plasma of MM patients. Myeloma cells from patients expressed CD39, and high gene expression indicated reduced survival.

  8. www.researchgate.net › Richard-Woessner-49528900Richard Woessner's research works | Array BioPharma Inc ...

    Richard Woessner's 17 research works with 650 citations and 1,831 reads, including: Discovery of a Novel Class of Imidazo[1,2- a ]Pyridines with Potent PDGFR Activity and Oral Bioavailability